Amgen Inc (AMGN) 115.39 $AMGN
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Thu Jul 17, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.
Midday Glance: Biotechnology companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Will Incoming Competition Derail Aegerion Stock?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Aegerion markets just one drug, Juxtapid, but the success or failure of that one drug is a hotbed for debate among investors. Enthusiasm following the FDA green-light of Juxtapid in December 2012 helped shares skyrocket to more than $90 per...
Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.78%
Comtex SmarTrend(R) - Tue Jul 15, 3:50PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $116.57 to a high of $119.47. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Amgen After 1.78% Loss
Comtex SmarTrend(R) - Tue Jul 15, 3:49PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $116.57 to a high of $119.47. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Amgen (AMGN) Roof Leaking Today
at The Street - Tue Jul 15, 10:21AM CDT
Trade-Ideas LLC identified Amgen (AMGN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Critical Alerts For Citigroup, BlackBerry, RF Micro Devices, Amgen, and Microsoft Released By InvestorsObserver
PR Newswire - Tue Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for C, BBRY, RFMD, AMGN, and MSFT.
Cytokinetics Up on Positive Tirasemtiv Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 4:00PM CDT
Cytokinetics Incorporated's (CYTK) shares jumped over 7% on Jul 11 after it announced that additional results from the BENEFIT-ALS study.
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
PR Newswire - Thu Jul 17, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. Amgen obtained AMG 416 as part of the acquisition of KAI Pharmaceuticals, Inc. in July 2012 and these are the first results to be reported from the Phase 3 program.
Midday Glance: Biotechnology companies
AP - Thu Jul 17, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Thu Jul 17, 9:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Will Incoming Competition Derail Aegerion Stock?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Aegerion markets just one drug, Juxtapid, but the success or failure of that one drug is a hotbed for debate among investors. Enthusiasm following the FDA green-light of Juxtapid in December 2012 helped shares skyrocket to more than $90 per...
Astellas Up on Pipeline Update, Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 2:03PM CDT
Astellas Pharma, Inc.'s (ALPMY) shares gained 2.5% following the company's update on its pipeline and corporate strategy late last week.
Stock Market News for July 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 9:10AM CDT
Benchmarks finished on a mixed note on Tuesday after a Fed monetary policy report sparked concerns about “substantially stretched valuations” in Internet and bio-tech stocks
Amgen Set to Possibly Rebound After Yesterday's Selloff of 1.78%
Comtex SmarTrend(R) - Tue Jul 15, 3:50PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $116.57 to a high of $119.47. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Amgen After 1.78% Loss
Comtex SmarTrend(R) - Tue Jul 15, 3:49PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $116.57 to a high of $119.47. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.88 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Amgen (AMGN) Roof Leaking Today
at The Street - Tue Jul 15, 10:21AM CDT
Trade-Ideas LLC identified Amgen (AMGN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Critical Alerts For Citigroup, BlackBerry, RF Micro Devices, Amgen, and Microsoft Released By InvestorsObserver
PR Newswire - Tue Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for C, BBRY, RFMD, AMGN, and MSFT.
Cytokinetics Up on Positive Tirasemtiv Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 4:00PM CDT
Cytokinetics Incorporated's (CYTK) shares jumped over 7% on Jul 11 after it announced that additional results from the BENEFIT-ALS study.
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
